AVDL News and Press, Avadel Pharmaceuticals plc From 08/10/20

Presented positive topline data from the pivotal Phase 3 REST-ON study Announced today that results of the data analyses for the secondary endpoints of the REST-ON study were consistent with the primary analyses and further demonstrated the overall statistical significance of FT218 co...

Quick Take Harmony Biosciences Holdings ( HRMY ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The firm is a biopharma commercializing its WAKIX molecule for the treatment of excessive sleepiness in adult narcolepsy. HRMY has...

DUBLIN, Ireland, July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10, 2020, to provide a corporate update and discuss the Company's financial results for the sec...

Last week, we provided a ' deep dive ' on Jazz Pharmaceuticals ( JAZZ ). After the research, we passed on making any investment recommendation on the mid-cap biopharma. In part, this was because there was a potentially better candidate in the pipeline of a much smaller biopharma that could b...

Equillium Reports Positive Data for COVID-19 Drug Trial Equillium Inc. (EQ) reported positive data for its COVID-19 drug itolizumab. The data showed that the drug candidate was useful in lowering the risk of mortality in patients suffering from coronavirus. The results were declared by i...

Avadel Pharmaceuticals ( AVDL +0.9% ) has  dosed first patient in an open-label extension/switch study of FT218, a once-nightly formulation of sodium oxybate, for excessive daytime sleepiness and cataplexy in patients with narcolepsy. More news on: Avadel Pharmaceuticals plc...

Clinical study to enroll 250 patients from sites that participated in the REST-ON study Study to examine the long-term safety and maintenance of efficacy in patients, and evaluate dosing and preference for patients switching from twice-nightly sodium oxybate to once-nightly FT218 ...

Fate is just another word for people's choices coming to a head. Destiny, coincidence, whatever you name it. It inevitably lies in our hands ." - Tiffanie DeBartolo It has been quite a while since we looked at this mid-cap biopharma below. The shares have seen better days, but there are s...

Avadel Pharmaceuticals ( AVDL -1.4% ) sold its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz, Vazculep, and Akovaz, as well as Nouress to Exela Sterile Medicines LLC for a total of $42M. More news on: Avadel Pharmaceu...

DUBLIN, Ireland, July 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today...